Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217722 | 0.90 | ADORA3 (0.40) | ADORA1ADORA2AADORA2BADORA3NT5E | |
| SCHEMBL4220348 | 0.87 | ADORA2A (0.47) | ADORA1ADORA2AADORA2BADORA3 | |
| Trifluoroacetic Acid SCHEMBL3904403 | 0.86 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL3905304 | 0.85 | ADORA2A (0.63) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2809155 | 0.83 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL4230273 | 0.83 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL3913337 | 0.83 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2832621 | 0.83 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2811066 | 0.83 | ADORA1 (0.44) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2811069 | 0.83 | ADORA1 (0.44) | ADORA1ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | claimed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | claimed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | claimed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA1 3/4885ADORA2A 1/4885ADORA2B 4/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | ADORA1 838/4885ADORA2A 2314/4885ADORA2B 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.